MedPath

The study of 99mTc-radiolabeled peptide for breast cancer imaging

Phase 2
Conditions
C50.91
Breast cancer.
Malignant neoplasm of breast of unspecified site, female
Registration Number
IRCT20141006019423N3
Lead Sponsor
Mazandaran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
250
Inclusion Criteria

Female
breast cancer
Without biopsy history

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Radiotracer uptake by breast cancer. Timepoint: Imaging of the breast at 1,2,3 and 4 hours after the administration of the radiolabeled peptide. Method of measurement: Imaging.;Distribution of radiolabeled peptide in other tissues. Timepoint: Imaging at 1,2,3 and 4 hours after the administration of the radiolabeled peptide. Method of measurement: Imaging.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath